Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Capstone Holding's Business Segments
Capstone Holding's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
2
Largest Segment
TotalStone
Total Revenue
$ 13
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- TotalStone79.1%
- Carolina Stone Holdings18.2%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| TotalStone | $ 10 | 79.1% |
| Carolina Stone Holdings | $ 2 | 18.2% |
Description of Capstone Holding
Capstone Therapeutics Corp. is a biotechnology company that focuses on the development of innovative therapies for various diseases and health conditions. The company is headquartered in Tempe, Arizona and was founded in 198 It operates as a subsidiary of Orthobond Corporation.
Capstone Therapeutics primarily focuses on the research and development of therapeutic peptides, which are short chains of amino acids that can be used to target specific biological pathways or disease processes. Peptide-based therapies have gained significant attention in recent years due to their high specificity and efficacy with minimal side effects.
One of the key areas of focus for Capstone Therapeutics is wound healing and tissue regeneration. The company has developed a proprietary platform technology called AZX100, which is a synthetic peptide compound that has demonstrated potential in accelerating wound healing and promoting tissue repair. AZX100 works by modulating the activity of certain growth factors and receptors involved in the healing process.
In addition to wound healing, Capstone Therapeutics is also involved in the development of therapies for other indications such as fibrosis, dermatology, and ophthalmology. The company has a diverse pipeline of candidates at various stages of development, including preclinical and clinical trials. Their pipeline includes both proprietary compounds and collaborations with other pharmaceutical companies.
Capstone Therapeutics collaborates with academic institutions, research organizations, and industry partners to advance its research and development programs. The company has secured several strategic partnerships and licensing agreements to leverage their expertise and resources in developing and commercializing novel therapies.
In terms of commercialization, Capstone Therapeutics aims to bring its therapies to market through partnerships with established pharmaceutical companies. By collaborating with larger players in the industry, they can benefit from their marketing, distribution, and manufacturing infrastructure, which can significantly accelerate the time to market for their products.
The company is led by a team of experienced professionals in the biotechnology and pharmaceutical industry, who have a strong track record in developing and commercializing innovative therapies. They are committed to advancing the field of peptide therapeutics and improving patient outcomes through their research and development efforts.
Overall, Capstone Therapeutics Corp. is dedicated to developing innovative therapies that address significant unmet medical needs. With their focus on peptide-based therapeutics and collaborations with strategic partners, they aim to make a meaningful impact on the lives of patients suffering from various diseases and conditions.
Capstone Therapeutics primarily focuses on the research and development of therapeutic peptides, which are short chains of amino acids that can be used to target specific biological pathways or disease processes. Peptide-based therapies have gained significant attention in recent years due to their high specificity and efficacy with minimal side effects.
One of the key areas of focus for Capstone Therapeutics is wound healing and tissue regeneration. The company has developed a proprietary platform technology called AZX100, which is a synthetic peptide compound that has demonstrated potential in accelerating wound healing and promoting tissue repair. AZX100 works by modulating the activity of certain growth factors and receptors involved in the healing process.
In addition to wound healing, Capstone Therapeutics is also involved in the development of therapies for other indications such as fibrosis, dermatology, and ophthalmology. The company has a diverse pipeline of candidates at various stages of development, including preclinical and clinical trials. Their pipeline includes both proprietary compounds and collaborations with other pharmaceutical companies.
Capstone Therapeutics collaborates with academic institutions, research organizations, and industry partners to advance its research and development programs. The company has secured several strategic partnerships and licensing agreements to leverage their expertise and resources in developing and commercializing novel therapies.
In terms of commercialization, Capstone Therapeutics aims to bring its therapies to market through partnerships with established pharmaceutical companies. By collaborating with larger players in the industry, they can benefit from their marketing, distribution, and manufacturing infrastructure, which can significantly accelerate the time to market for their products.
The company is led by a team of experienced professionals in the biotechnology and pharmaceutical industry, who have a strong track record in developing and commercializing innovative therapies. They are committed to advancing the field of peptide therapeutics and improving patient outcomes through their research and development efforts.
Overall, Capstone Therapeutics Corp. is dedicated to developing innovative therapies that address significant unmet medical needs. With their focus on peptide-based therapeutics and collaborations with strategic partners, they aim to make a meaningful impact on the lives of patients suffering from various diseases and conditions.
Capstone Therapeutics Corp. is a biotechnology company known for its focus on the development of innovative therapies centered on therapeutic peptides. Below is an extensive overview of the segments, products, and services typically associated with Capstone Therapeutics Corp.
Segments
1. Peptide Therapeutics Development:
- Capstone Therapeutics focuses on discovering and developing peptide-based therapeutics that can address various unmet medical needs. This segment often includes the research and development of peptides that can modulate biological processes, and act as effective treatments for diseases.
2. Research and Development (R&D):
- The R&D segment is critical, emphasizing the creation of new molecules and the exploration of their therapeutic potential. This often includes pre-clinical and clinical studies aimed at understanding how peptide therapies can be utilized to treat specific conditions.
3. Collaboration and Partnerships:
- The company may engage in collaborations with research institutions, pharmaceutical companies, and healthcare organizations. These partnerships might focus on sharing research findings, co-developing products, or enhancing the reach of Capstones peptide-based therapies.
Products
1. Therapeutic Peptides:
- The hallmark of Capstone Therapeutics offerings is its portfolio of unique therapeutics derived from natural peptide sources. These products can be tailored for specific indications, such as metabolic disorders, cancer, wound healing, and other diseases.
2. Clinical Development Programs:
- The company could have several peptide candidates in different stages of clinical trials. These may include:
- Phase I Trials: Typically focused on safety and dosage in a small group of healthy volunteers or patients.
- Phase II Trials: Designed to assess the efficacy of the peptide in targeted patient populations, further evaluating safety, and determining optimal dosing.
- Phase III Trials: More extensive, these trials are usually conducted with larger populations to confirm effectiveness, monitor side effects, and compare to commonly used treatments.
Services
1. Consultative Services:
- Capstone Therapeutics may offer consultation for other biotech firms or research organizations looking to develop peptide therapeutics. This could involve guidance on peptide design, synthesis, and optimization strategies.
2. Commercialization and Licensing:
- The company might engage in licensing agreements with other pharmaceutical companies to commercialize its peptide products. This could include sharing rights for specific therapeutic areas, co-development agreements, and revenue-sharing arrangements.
3. Regulatory Affairs Consulting:
- Navigating the complex regulatory landscape is critical for any biotech firm. Capstone Therapeutics may assist partners with regulatory strategies, ensuring that their products comply with health authorities stringent demands from discovery through clinical development and into the market.
4. Manufacturing Support:
- The firm might have capabilities or partnerships for the scale-up manufacturing of their peptide products. This involves ensuring that production meets regulatory standards and quality control measures to guarantee the safety and efficacy of therapeutic peptides.
In summary, Capstone Therapeutics Corp. operates primarily within the biotechnology sector, with a concentrated focus on the research, development, and commercialization of peptide therapeutics. Their offerings are supported by comprehensive R&D activities, collaboration initiatives, and an extensive understanding of regulatory processes, positioning them at the forefront of innovative therapeutic development.
Segments
1. Peptide Therapeutics Development:
- Capstone Therapeutics focuses on discovering and developing peptide-based therapeutics that can address various unmet medical needs. This segment often includes the research and development of peptides that can modulate biological processes, and act as effective treatments for diseases.
2. Research and Development (R&D):
- The R&D segment is critical, emphasizing the creation of new molecules and the exploration of their therapeutic potential. This often includes pre-clinical and clinical studies aimed at understanding how peptide therapies can be utilized to treat specific conditions.
3. Collaboration and Partnerships:
- The company may engage in collaborations with research institutions, pharmaceutical companies, and healthcare organizations. These partnerships might focus on sharing research findings, co-developing products, or enhancing the reach of Capstones peptide-based therapies.
Products
1. Therapeutic Peptides:
- The hallmark of Capstone Therapeutics offerings is its portfolio of unique therapeutics derived from natural peptide sources. These products can be tailored for specific indications, such as metabolic disorders, cancer, wound healing, and other diseases.
2. Clinical Development Programs:
- The company could have several peptide candidates in different stages of clinical trials. These may include:
- Phase I Trials: Typically focused on safety and dosage in a small group of healthy volunteers or patients.
- Phase II Trials: Designed to assess the efficacy of the peptide in targeted patient populations, further evaluating safety, and determining optimal dosing.
- Phase III Trials: More extensive, these trials are usually conducted with larger populations to confirm effectiveness, monitor side effects, and compare to commonly used treatments.
Services
1. Consultative Services:
- Capstone Therapeutics may offer consultation for other biotech firms or research organizations looking to develop peptide therapeutics. This could involve guidance on peptide design, synthesis, and optimization strategies.
2. Commercialization and Licensing:
- The company might engage in licensing agreements with other pharmaceutical companies to commercialize its peptide products. This could include sharing rights for specific therapeutic areas, co-development agreements, and revenue-sharing arrangements.
3. Regulatory Affairs Consulting:
- Navigating the complex regulatory landscape is critical for any biotech firm. Capstone Therapeutics may assist partners with regulatory strategies, ensuring that their products comply with health authorities stringent demands from discovery through clinical development and into the market.
4. Manufacturing Support:
- The firm might have capabilities or partnerships for the scale-up manufacturing of their peptide products. This involves ensuring that production meets regulatory standards and quality control measures to guarantee the safety and efficacy of therapeutic peptides.
In summary, Capstone Therapeutics Corp. operates primarily within the biotechnology sector, with a concentrated focus on the research, development, and commercialization of peptide therapeutics. Their offerings are supported by comprehensive R&D activities, collaboration initiatives, and an extensive understanding of regulatory processes, positioning them at the forefront of innovative therapeutic development.